Table of Contents Table of Contents
Previous Page  378 / 812 Next Page
Information
Show Menu
Previous Page 378 / 812 Next Page
Page Background

S374

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

to them which can end with serious consequences. Online forum

content gives us a strong base understanding of users experiences

of SC. Further research is required to elucidate a more nuanced

understanding.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1059

EV75

The “Endless Trip”: Psychopathology

and psychopharmacology in the

Hallucinogen Persisting Perception

Disorder (HPPD)

L. Orsolini

1 ,

, A. Valchera

2

, D. Papanti

3

, R. Vecchiotti

1

,

D. De Berardis

4

1

Villa San Giuseppe Hospital- Hermanas Hospitalarias, Department

of Psychiatry, Ascoli Piceno, Italy

2

Villa San Giuseppe Hospital, Department of Psychiatry, Ascoli

Piceno, Italy

3

University of Hertfordshire, Department of Pharmacy, Hatfield,

United Kingdom

4

Hospital “G. Mazzini” – ASL 4, NHS – Department of Mental Health

– Psychiatric Service of Diagnosis and Treatment, Teramo, Italy

Corresponding author.

Introduction

Hallucinogen Persisting Perception Disorder

(HPPD) is a syndrome characterized by prolonged or reoccur-

ring perceptual symptoms, reminiscent of acute hallucinogen

effects. HPPD was associated with a broader range of LSD (lysergic

acid diethylamide)-like substances, including cannabis, MDMA

(methylenedioxymethamphetamine), psilocybin, mescaline and

other psychostimulants. Symptomatology mainly comprises visual

disorders (i.e., geometric pseudo-hallucinations, halos, flashes of

colours/lights, motion-perception deficits, afterimages, micropsy,

more acute awareness of floaters, etc.), even though depressive

symptoms and thought disorders may be comorbidly present.

Objective

Although HPPD was firstly described in 1954, it was

definitely established as a syndrome in 2000 with the revised

forth version of the Diagnostic and Statistical Manual of Mental

Disorders (DSM-IV-TR). However, neuronal substrate, risk factors,

aetiology and pathogenesis of HPPD remains still unknown and

under investigation. Furthermore, there are still open questions

about its pharmacological targets.

Aims

A critical review on psychopathological bases, etiological

hypothesis and psychopharmacological approaches towards HPPD

was here provided.

Methods

A systematic literature search on PubMed/Medline,

GoogleScholar and Scopus databases without time restrictions, by

using a specific set of keywords was here carried out. In addition, a

case report was here described.

Results and conclusions

Pharmacological and clinical issues are

here considered and practical psychopharmacological recommen-

dations and clinical guidelines here suggested.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1060

EV76

Psychosis and polydrug abuse in a

patient with Dandy-Walker variant

L. Orsolini

1 , 2 , 3 , 4 ,

, A. Valchera

1 , 4

, R. Vecchiotti

1 , 2 , 4

,

M. Panichi

1 , 4

, D. De Berardis

5 , 6

1

Villa San Giuseppe Hospital – Hermanas Hospitalarias, Department

of Psychiatry, Ascoli Piceno, Italy

2

Maastricht University, Department of Psychiatry and

Neuropsychology, Maastricht, Netherlands

3

School of Life and Medical Sciences- University of Hertfordshire,

Department of Pharmacy, Hatfield, United Kingdom

4

Polyedra, Polyedra Research, Teramo, Italy

5

Ital “G. Mazzini” – ASL 4 Teramo, NHS – Department of Mental

Health, Psychiatric Service of Diagnosis and Treatment, Teramo, Italy

6

University of “G. D’Annunzio”, Department of Neuroscience –

Imaging and Clinical Science, Chieti, Italy

Corresponding author.

Background and purpose

Dandy Walker “syndrome” (DWS) was

firstly defined by Dandy and Blackfan, and then described by

Hart et al. [1] as a series of neurodevelopmental anomalies in

the posterior fossa, including Dandy-Walker (DW) malformation,

DW variant (cerebellar hypoplasia/aplasia of the cerebellar vermis

and cystic dilatation of the fourth ventricle), mega-cisterna magna

and posterior fossa arachnoid cyst. Mental symptoms have been

associated with DWS in previous reports, but the spectrum of men-

tal symptomatology widely varies between clinical cases, ranging

from psychotic/schizophrenia-like to mood/cognitive symptoms

[2].

Methods

Here we describe a case of psychosis and polydrug

abuse in a 27-year-old man with DW variant a 4-year history of

polydrug abuse, sporadic alcohol abuse, epilepsy and psychotic

symptoms including delusions of reference/persecution, suspi-

ciousness, associated with obsessive thoughts, mood lability and

persistent anxiety.

Results

He was recovered for a 28-day program of detoxifica-

tion from drug addiction/stabilization of psychiatric symptoms.

Family history of Bipolar Disorder, gambling disorder (father)

and depression (mother). The mental status examination at

baseline revealed slowness of thought, psychomotor retardation,

aboulia/anhedonia/apathy/hypomimic facies/asthenia/social with-

drawal/deflected mood/poor thought content/blunted affect/self-

neglect/poor insight, cognitive impairment and oppositive and

partially collaborative attitude and behaviour. Borderline intel-

ligence activity was found on WAIS-R (IQ = 79). At the baseline,

he was taking carbamazepine 400mg BID (baseline serum level:

6.720 g/ml), gabapentin (400mg BID), paroxetine (20mg/d),

olanzapine (10mg/d) and methadone (70ml/d), with a poor

response/control both on psychotic and seeking drug symptoma-

tology.

References not available.

Conclusions

Further DWS clinical cases should be evaluated in

order to better investigate the role of this variant to addictive and

psychotic symptoms.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1061

EV77

Improved drug-use patterns at six

months post discharge from inpatient

substance use disorder treatment;

results from compulsory and

voluntary admitted patients

A. Pasareanu

, J.K. Vederhus , O. Kristensen , T. Clausen , A. Opsal

Sørlandet Hospital Kristiansand, Addiction Unit, Kristiansand,

Norway

Corresponding author.

Background

The Norwegian Municipal Health Care Act opens for

mandated treatment for persons with severe and life-threatening

substance use disorder. This study aims to examine substance use

related outcomes at six-month following in-patient treatment and

to analyse factors associated with improved outcomes and absti-

nence.

Method

This prospective study followed 202 hospitalised

patients with SUD that were admitted voluntarily (

n

= 137) or